# US 2025/0152558 A1 · Stable pharmaceutical compositions of clonidine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152558 A1
- Document ID: US20250152558A1
- Status: Published application
- Kind: A1
- Application number: 19/021,882
- Filed: 2025-01-15
- Published: 2025-05-15
- Earliest claimed: 2021-11-15
- Assignees: Slayback Pharma LLC
- Applicants: Slayback Pharma LLC
- Inventors: Shailendra MANDGE; Harish GUNDA; Naga Venkata Durga Prasad KETHA; Venkateshwar Reddy KEESARA; . Satheesh Balasubramanian; Sumitra Ashokkumar PILLAI
- Web page: https://patentgrep.com/patent/US20250152558A1

## CPC

- A61K 31/4168: having a nitrogen attached in position 2, e.g. clonidine
- A61J 1/065: {Rigid ampoules, e.g. glass ampoules}
- A61J 1/1468: {Containers characterised by specific material properties}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE

## Abstract

The present invention relates to liquid pharmaceutical compositions of clonidine or its pharmaceutically acceptable salts thereof. Preferably, the liquid pharmaceutical compositions are suitable for oral administration, and are stable for extended periods of time. More specifically, stable liquid pharmaceutical compositions of clonidine at concentrations of 1 μg/mL or more are provided. The present invention further relates to stable oral liquid compositions of clonidine, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by clonidine.

## Claims

### Claim 1

A liquid pharmaceutical composition consisting of:
(a) clonidine hydrochloride at a concentration of about 20 μg/mL;
(b) stabilizer at a concentration of about 0.001% to 20% w/v, based on total weight of the composition;
(c) a preservative at a concentration of about 0.01% to 5.0% w/v, based on total weight of the composition;
(d) a sweetener;
(e) a flavoring agent; and
(f) water; and
(g) optionally, a pH adjusting agent;
wherein said composition is free of buffer;
wherein said composition is an oral solution; and
wherein not more than 2% w/w of total impurities are formed when said composition is stored for at least 3 months at 25° C./40% RH or 25° C./60% RH.

### Claim 2 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein the said stabilizer is selected from the group consisting histidine, arginine, meglumine, tromethamine, sodium chloride or mixtures thereof.

### Claim 3 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein the preservative is potassium sorbate and/or sodium propionate at a concentration of 2.5 mg/mL.

### Claim 4 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein the sweetener is sucralose.

### Claim 5 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein the pH is from about 3 to about 9.

### Claim 6 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein the pH is from about 4 to about 6.

### Claim 7 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein a concentration of the stabilizer is from 01% to 15.0% w/w, based on total weight of the composition.

### Claim 8 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein a concentration of the stabilizer is from 0.1% to 10.0% w/w, based on total weight of the composition.

### Claim 9 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein a weight ratio of clonidine hydrochloride to stabilizer ranges from about 1:50 to about 1:150.

### Claim 10 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein a weight ratio of clonidine hydrochloride to stabilizer is about 1:125.

### Claim 11 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein a concentration of the preservative ranges from 0.05% to 1.0%, based on total weight of the composition.

### Claim 12 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein a weight ratio of clonidine hydrochloride to preservative is from about 1:20 to about 1:70.

### Claim 13 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein a weight ratio of clonidine hydrochloride to preservative is about 1:50.

### Claim 14 (depends on 1)

The liquid pharmaceutical composition according to claim 1, wherein said composition exhibits in-use shelf life of at least one month when stored at room temperature.

### Claim 15 (depends on 1)

A multi-dose container comprising the liquid pharmaceutical composition according to claim 1.

### Claim 16 (depends on 15)

A multi-dose container comprising the liquid pharmaceutical composition according to claim 15, wherein the container is a polyethylene terephthalate (PET) bottle.

### Claim 17 (depends on 15)

A multi-dose container comprising the liquid pharmaceutical composition according to claim 15, wherein the container is a high-density polyethylene (HDPE) bottle.

### Claim 18 (depends on 15)

A multi-dose container comprising the liquid pharmaceutical composition according to claim 15, wherein the container is a glass bottle.

### Claim 19 (depends on 15)

A multi-dose container comprising the liquid pharmaceutical composition according to claim 15, wherein the container comprises blow-fill sealed vials.
